www.onclive.com Open in urlscan Pro
76.76.21.142  Public Scan

Submitted URL: http://www.onclive.com/
Effective URL: https://www.onclive.com/
Submission: On February 05 via api from US — Scanned from DE

Form analysis 1 forms found in the DOM

GET /search

<form method="GET" action="/search">
  <div class="relative">
    <div class="text-gray-600 absolute ml-3 inset-0 m-auto lg:w-4 lg:h-4 md:w-6 md:h-6"><button aria-label="submit" type="submit" class="absolute block inset-0"><svg xmlns="http://www.w3.org/2000/svg"
          class="text-gray-600 stroke-current icon icon-tabler icon-tabler-search" viewBox="0 0 24 24" stroke-width="2" stroke="currentColor" fill="none" stroke-linecap="round" stroke-linejoin="round">
          <path stroke="none" d="M0 0h24v24H0z"></path>
          <circle cx="10" cy="10" r="7"></circle>
          <line x1="21" y1="21" x2="15" y2="15"></line>
        </svg></button></div><input type="text" required="" name="searchTerm" class="block border border-gray-200 focus:outline-none focus:border-indigo-700 lg:w-48 xl:w-64 rounded text-sm text-gray-800 pl-8 py-2" placeholder="Search">
  </div>
</form>

Text Content

News
OncClubAll Oncology NewsPipeline Report
Media
InsightsMedical World NewsOncChatsOncLive News Network®OncLive TVPeer
ExchangePodcastsRapid ReadoutsThe Talk
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CarePER EventsScientific InterchangesState of the Science
Summit / IPCWebinars
Partners
Publications
Oncology Live®Oncology FellowsSupplements And Featured PublicationsAll
Publications
CME/CE
Resources
Interactive ToolsLearning ModulesPresentationsSponsored
Biomarker Consortium
Subscribe
Print SubscriptioneNewsletter

Choose Specialty
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic
OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
Spotlight -
 * In-person and virtual events just for HCPs

Choose Specialty
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic
OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
 * * Spotlight
   * News
   * Media
   * Conferences
   * Events
   * Partners
   * Publications
   * CME/CE
   * Resources
   * Biomarker Consortium
   * Subscribe


Advertisement


--------------------------------------------------------------------------------


LATEST NEWS


World Cancer Day Highlights Ways to Address Gaps in Care for Black Patients With
Breast Cancer
By Ryan Scott
February 4th 2024

World Cancer Day is held every year on February 4th, prompting individuals
across the globe to expand awareness within cancer care.

Linvoseltamab Continues to Elicit Durable Efficacy in High-Risk
Relapsed/Refractory Multiple Myeloma
By Ryan Scott
February 3rd 2024
Pirtobrutinib Continues to Show Safety, Activity in Covalent BTK
Inhibitor–Pretreated R/R MCL
By Courtney Flaherty
February 3rd 2024
EMA Validates MAA for Tisotumab Vedotin in Recurrent or Metastatic Cervical
Cancer
By Kristi Rosa
February 2nd 2024
FDA Grants Orphan Drug Designation to Efineptakin Alfa for Pancreatic Cancer
By Kristi Rosa
February 2nd 2024
Latest Videos
Unmet Needs in the Allogeneic Hematopoietic Stem Cell Transplant Population

Dr Mikhael on Unmet Needs in Cancer Care for Patients With Multiple Myeloma

Clinical Case 4: Radiation Therapy

Sequencing With CAR T-Cell Therapy for LBCL

Dr Halmos on Treatment Strategies For EGFR-Mutant NSCLC

Dr Siegel on the Importance of Closing the Gaps in Cancer Care

Dr Curran on Developing Strategies for Stage III NSCLC Management

Dr Simon on the Utility of Novel Treatments in Diverse Patient Populations With
Cancer

Dr Levy on Unanswered Questions Regarding the Mechanism of Action of ADCs in
NSCLC

Dr Leal on the Development of DLL3-Targeted Agents in SCLC

Dr Pellini on the Development of Increasingly Sensitive ctDNA Assays in NSCLC

Dr Rodriguez on the Use of HER2-Directed Therapies in NSCLC

Dr George on the CheckMate 8Y8 Trial of Nivolumab With/Without Ipilimumab in
Untreated RCC

Dr Castillo on Acalabrutinib Plus Rituximab in Patients With Anti-MAG IgM
Peripheral Neuropathy

Patient Case Studies of GvHD

Treatment Resistance with Covalent BTKis: Translating Data into Clinical
Practice

Expert Insights into Navigating Cardiovascular Risks with BTKi Therapy

Dr Yu discusses the ARCAD Nomogram in a Real-World CRC Population

Dr Bryant on the Background For Investigating Germline DNA Repair Mutations in
PDAC

Dr Yaeger on the Background of the CodeBreaK 101 Trial in mCRC

Biomarker Consortium Videos
Key Elements of an NGS Testing Report

Interpreting the Results of an NGS Testing Report

How is Biomarker Testing Performed and Utilized?

Addressing Concerns Regarding Biomarker Testing

Tissue and Plasma-Based Mechanisms of Resistance to First-Line Osimertinib in
EGFR-Mutant NSCLC: A Multi-Institutional Cohort

Predictive Biomarkers for Treatment With Amivantamab Plus Lazertinib Among
EGFR-Mutated NSCLC in the Post-Osimertinib Setting: Analysis of Tissue IHC and
ctDNA NGS

Real-World Testing and Treatment Patterns Among Patients With Stage IV NSCLC: A
Retrospective Observational Study

Contemporary Biomarker Testing Rates in Both Early and Advanced NSCLC: Results
From the MYLUNG Pragmatic Study

What is NGS Testing?

What is DNA and RNA Testing in Biomarker Testing?

Why Are You Choosing a Certain Testing Platform in Biomarker Testing?

How Do You Explain Adjuvant Therapy in NSCLC?

When Should Patients With NSCLC be Referred to Thoracic Surgeons in Specialized
Centers of Care?

What are the Benefits and Side Effects of TKIs?

What is a Biomarker in the Context of Tumors?

What is a Gene Mutation and a Gene Fusion?

What is a Chromosomal Rearrangement?

How Do You Explain Neoadjuvant Therapy in NSCLC?

What are Challenges Around Access to Testing?

What are the Benefits and Side Effects of Immunotherapy?

Latest CME Events & Activities

In-Person EventCME,CNE

21st Annual Winter Lung Cancer Conference®

February 2-4, 2024

Register Now!




Archived WebcastCME

Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current
Barriers and Opportunities for Improved Outcomes

View More




Archived WebcastCME

Keeping Pace with Rapid Advancements in Multiple Myeloma Care

View More




Oncology Town Hall®CME

Oncology Town Hall™: Primary Investigators Present Key Abstracts in the
Management of CLL

View More




Community Practice Connections™CME

Maximizing Our Clinical Practices in Hodgkin Lymphoma: Integration of Recent
Data Sets in Real World Settings

View More




Community Practice Connections™CME

Community Practice Connections™: Matching the Tumor With Patient-Specific Goals
to Inform Frontline Selection and Sequencing in Chronic Lymphocytic Leukemia

View More




Community Practice Connections™CME,CPE

State-of-the-Art CMV Care: Experts’ Perspectives on Primary/Secondary Prevention
and Management of Refractory/Resistant Infections

View More




Clinical Vignette Series™CME,CNE

Clinical Vignettes: Inaugural International Congress on Pediatric Oncology

View More






ALL ONCOLOGY NEWS



A-Plus Machine Learning Approach Displays Accurate Cancer Detection With Smaller
Sample Amounts

By Kyle Doherty
February 2nd 2024


Investigators have developed a machine learning algorithm that could eventually
facilitate earlier cancer detection via smaller blood draws.



EMA Accepts Marketing Authorization Application for Linvoseltamab in R/R
Multiple Myeloma

By Caroline Seymour
February 2nd 2024


The EMA has accepted for review an MAA seeking the approval of linvoseltamab for
use in select patients with relapsed/refractory multiple myeloma.



Lenvatinib/Pembrolizumab Maintained Beneficial Outcomes When Evaluated by Tumor
Size in RCC

By Ryan Scott
February 2nd 2024


Lenvatinib/pembrolizumab demonstrated efficacy irrespective of tumor burden in
advanced renal cell carcinoma in the overall patient population of the phase 3
CLEAR study.



Elevated Blood Levels of NT-proBNP in Cancer Survivors Link With Higher Risks of
Death

By Dana-Farber Cancer Institute
February 2nd 2024


Cancer survivors with elevated levels of NT-proBNP have a higher risk of death,
according to an analysis conducted by Dana-Farber Cancer Institute.



Lonial Spotlights CAR T-Cell and Off-the-Shelf Treatments in Multiple Myeloma

By Megan Hollasch
February 2nd 2024


Sagar Lonial, MD, FACP, details how CAR T-cell therapies and off-the-shelf
treatments are improving outcomes for patients with multiple myeloma.



Japanese Approval Sought for Enfortumab Vedotin Plus Pembrolizumab in Urothelial
Cancer

By Kristi Rosa
February 2nd 2024


A sNDA seeking approval of enfortumab vedotin plus pembrolizumab for first-line
use in patients with urothelial cancer has been submitted to Japan’s MHLW.



SCO-101 Plus FOLFIRI Shows Signs of Efficacy in Metastatic Colorectal Cancer

By Kristi Rosa
February 1st 2024


The combination of SCO-101 and FOLFIRI resulted in tumor reduction and increased
progression-free survival in patients with metastatic colorectal cancer.



Camidge and Okuyama Sasaki Highlight How Safety Net Hospitals Widen the Scope of
Cancer Care

By OncLive Staff
February 1st 2024


Drs Camidge and Okuyama Sasaki discuss the goals of safety net hospitals and the
dynamics of helping low-income patients access cancer treatments.



Physician Expectations Regarding the FDA Approval Process May Differ From
Reality

By Megan Hollasch
February 1st 2024


Sanket Dhruva, MD, MHS, details examining the perspectives of physicians
regarding the FDA approval process for drugs and high-risk medical devices.



FDA Grants Priority Review to Afami-Cel BLA in Advanced Synovial Sarcoma

By Ryan Scott
February 1st 2024


The FDA has accepted for priority review the BLA seeking the approval of
afamitresgene autoleucel for the treatment of advanced synovial sarcoma.



FDA Grants Fast Track Designation to BST02 for Liver Cancer

By Caroline Seymour
February 1st 2024


The FDA has granted a fast track designation to the T-cell therapy BST02 for the
treatment of patients with all forms of liver cancer.



SABCS 2023 Findings Build on Positive Momentum in HER2+ Breast Cancer

By Kyle Doherty
February 1st 2024


Expert oncologists in the field of breast cancer review data in HER2-positive
early-stage and metastatic breast cancer.



Updated CheckMate 649 Data Reinforce Nivolumab Plus Chemo as Frontline SOC in
Advanced Gastric Cancers

By Courtney Flaherty
February 1st 2024


Kohei Shitara, MD, discusses 4-year survival data of chemotherapy plus nivolumab
in advanced gastric/GEJ cancer or esophageal adenocarcinoma.



Investigators Set to Explore Selinexor Monotherapy or Plus Ruxolitinib in JAK
Inhibitor–Naive Myelofibrosis

By Ashling Wahner
January 31st 2024


Selinexor is under investigation as monotherapy and in combination with the JAK
inhibitor ruxolitinib in patients with JAK inhibitor–naive myelofibrosis.



Ziftomenib Combos Show Early Safety, Activity in NPM1-Mutant and
KMT2A-Rearranged AML

By Kristi Rosa
January 31st 2024


An acceptable safety profile and early evidence of clinical activity was
observed with ziftomenib plus standard regimens in select patients with AML.



Garmezy Highlights Ongoing and Future Research Directions Across RCC Subtypes

By Courtney Flaherty
January 31st 2024


Benjamin Garmezy, MD, provides an overview of recent data on immuno-oncology/TKI
combination data in variant renal cell carcinoma.



KRAS G12C–Targeted Therapies May Move Earlier in the mCRC Treatment Sequence

By Ashling Wahner
January 31st 2024


Rona Yaeger, MD, discusses a study of second-line sotorasib plus panitumumab in
patients with KRAS G12C–mutated colorectal cancer.



sBLA Submitted to FDA for Subcutaneous Daratumumab Plus VRd in
Transplant-Eligible Multiple Myeloma

By Kyle Doherty
January 31st 2024


A sBLA seeking the approval of D-VRd for transplant-eligible patients with newly
diagnosed multiple myeloma was submitted to the FDA.



Actionable Molecular Findings: Increasingly Clinically Relevant but Also
Increasingly Complex

By Maurie Markman, MD
January 31st 2024


Maurie Markman, MD, discusses the need for a decision support strategy to assist
oncologists in treatment selection for patients with actionable mutations.



FDA Grants Priority Review to Adjuvant Alectinib for Early-Stage ALK+ NSCLC

By Kristi Rosa
January 31st 2024


The FDA granted priority review to a sNDA seeking the approval of alectinib as
adjuvant treatment after surgery for early-stage ALK-positive NSCLC.



ELAINE-3 Trial Sets Out to Confirm Clinical Benefit of Lasofoxifene/Abemaciclib
in ESR1-Mutant, ER+ Breast Cancer

By Courtney Flaherty
January 30th 2024


Seth A. Wander, MD, PhD, discusses key findings with lasofoxifene from ELAINE-1
and ELAINE-2 that supported the initiation of the ELAINE-3 trial.



FDA Grants Priority Review to Expand Liso-Cel Indications in R/R Follicular
Lymphoma and MCL

By Kristi Rosa
January 30th 2024


Liso-cel sBLAs for indications in relapsed/refractory FL and MCL after exposure
to a BTK inhibitor have received priority review from the FDA.



Hobbs Highlights Key Research in Hematologic Malignancies at the 2023 ASH Annual
Meeting

By Courtney Flaherty
January 30th 2024


Gabriela Hobbs, MD, discusses the significance of key research across
myeloproliferative neoplasms from the 2023 ASH Annual Meeting.



EMA Validates Application for First-Line Enfortumab Vedotin Plus Pembrolizumab
in Urothelial Cancer

By Courtney Flaherty
January 30th 2024


The type II variation application for enfortumab vedotin plus pembrolizumab in
untreated metastatic urothelial cancer has been validated by the EMA.



Targeted Agents and Combination Therapies May Open Doors in MDS Management

By Ashling Wahner
January 30th 2024


Talha Badar, MBBS, MD, discusses the FDA approval of ivosidenib for patients
with myelodysplastic syndrome and the future management of this disease.


See All News >
Advertisement



LATEST CONFERENCE COVERAGE

Dr Halmos on Treatment Strategies For EGFR-Mutant NSCLC



Dr Curran on Developing Strategies for Stage III NSCLC Management



Dr Levy on Unanswered Questions Regarding the Mechanism of Action of ADCs in
NSCLC



Dr Leal on the Development of DLL3-Targeted Agents in SCLC

View More Latest Conference Coverage
Advertisement

Recent Content

World Cancer Day Highlights Ways to Address Gaps in Care for Black Patients With
Breast Cancer



Linvoseltamab Continues to Elicit Durable Efficacy in High-Risk
Relapsed/Refractory Multiple Myeloma



Pirtobrutinib Continues to Show Safety, Activity in Covalent BTK
Inhibitor–Pretreated R/R MCL



EMA Validates MAA for Tisotumab Vedotin in Recurrent or Metastatic Cervical
Cancer

View More Recent Content
Advertisement

x

Advertise
About OncLive
Editorial Board
CancerNetwork.com
CGTlive.com
CureToday.com
OncNursingNews.com
TargetedOnc.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777



© 2024 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact